Assessing Antimicrobial Consumption in Public and Private Sectors Within the Costa Rican Health System: Current Status and Future Directions

Overview

Journal BMC Public Health

Publisher Biomed Central

Specialty Public Health

Date 2024 Nov 19

PMID 39558349

Authors

Jose Pablo Diaz-Madriz

Carolina Rojas-Chinchilla

Esteban Zavaleta-Monestel

Shing Mi Ching-Fung

Hugo Marin-Piva

Gustavo H Marin

Lucia Giangreco

Affiliations

Soon will be listed here.

Abstract

Background: Antimicrobial resistance is a significant global health threat. Therefore, robust surveillance systems for antimicrobial consumption (AMC) are essential to develop public health strategies. However, Latin American countries, including Costa Rica, face challenges in regularly reporting AMC data. This study aims to estimate and analyse the overall AMC in Costa Rica for 2019.

Methods: This study is a national-level, retrospective, observational, and descriptive analysis of AMC in Costa Rica from 1 January to 31 December 2019. The study followed the World Health Organization (WHO) guidelines for the Surveillance of National AMC. The Anatomical Therapeutic Chemical (ATC) / Defined Daily Doses (DDD) system was used to analyse types of antimicrobials and DDD per 1000 inhabitants per day (DID). Antimicrobial dispensation data from the Costa Rican Social Security Fund (CCSS) represented the public sector, while the private sector data was sourced from IQVIA. The analysis included data from both inpatient and outpatient sectors.

Results: A total AMC of 14.32 DID, of which 12.75 DID was within the public sector and 4.12 DID was within the private sector. Penicillins had the highest consumption nationally and in the public sector, while macrolides and lincosamides predominate in the private sector. According to the WHO-AWaRe (Access-Watch-Reserve) classification, antibiotics predominantly consumed nationally (74.7%) and in the public (83.0%) sectors are categorized under Access, whereas the private (61.0%) sector predominates the Watch category.

Conclusion: This study illustrates the importance of enhancing AMC surveillance by integrating data from both the public and private sectors. The findings indicate an excessive use of "Watch" antimicrobials in the private sector. To address this issue, all sectors and regulatory authorities must play an active and supportive role, in the development of effective, multisectoral policies. The methodology employed in this study is applicable to other Latin American countries, and therefore should be utilized for future analysis AMC in this region.

References

Yaghoubi S, Zekiy A, Krutova M, Gholami M, Kouhsari E, Sholeh M . Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. Eur J Clin Microbiol Infect Dis. 2021; 41(7):1003-1022. PMC: 7785128. DOI: 10.1007/s10096-020-04121-1. View

Wirtz V, Dreser A, Gonzales R . Trends in antibiotic utilization in eight Latin American countries, 1997-2007. Rev Panam Salud Publica. 2010; 27(3):219-25. DOI: 10.1590/s1020-49892010000300009. View

Jayatilleke K . Challenges in Implementing Surveillance Tools of High-Income Countries (HICs) in Low Middle Income Countries (LMICs. Curr Treat Options Infect Dis. 2020; 12(3):191-201. PMC: 7453076. DOI: 10.1007/s40506-020-00229-2. View

Zarb P, Ansari F, Muller A, Vankerckhoven V, Davey P, Goossens H . Drug utilization 75% (DU75%) in 17 European hospitals (2000-2005): results from the ESAC-2 Hospital Care Sub Project. Curr Clin Pharmacol. 2011; 6(1):62-70. DOI: 10.2174/157488411794941322. View

Leung A, Wong A, Hon K . Community-Acquired Pneumonia in Children. Recent Pat Inflamm Allergy Drug Discov. 2018; 12(2):136-144. DOI: 10.2174/1872213X12666180621163821. View

Seale A, Gordon N, Islam J, Peacock S, Scott J . AMR Surveillance in low and middle-income settings - A roadmap for participation in the Global Antimicrobial Surveillance System (GLASS). Wellcome Open Res. 2017; 2:92. PMC: 5645727. DOI: 10.12688/wellcomeopenres.12527.1. View

Duran C, Christiaens T, Acosta A, Vander Stichele R . Systematic review of cross-national drug utilization studies in Latin America: methods and comparability. Pharmacoepidemiol Drug Saf. 2015; 25(1):16-25. DOI: 10.1002/pds.3896. View

Claeys K, Hopkins T, Vega A, Heil E . Fluoroquinolone Restriction as an Effective Antimicrobial Stewardship Intervention. Curr Infect Dis Rep. 2018; 20(5):7. DOI: 10.1007/s11908-018-0615-z. View

Adebisi Y . Balancing the risks and benefits of antibiotic use in a globalized world: the ethics of antimicrobial resistance. Global Health. 2023; 19(1):27. PMC: 10116465. DOI: 10.1186/s12992-023-00930-z. View

10.

Marin G, Giangreco L, Dorati C, Mordujovich P, Boni S, Mantilla-Ponte H . Antimicrobial Consumption in Latin American Countries: First Steps of a Long Road Ahead. J Prim Care Community Health. 2022; 13:21501319221082346. PMC: 9021473. DOI: 10.1177/21501319221082346. View

11.

. Ten great public health achievements--United States, 1900-1999. MMWR Morb Mortal Wkly Rep. 1999; 48(12):241-3. View

12.

Liu E, Linder K, Kuti J . Antimicrobial Stewardship at Transitions of Care to Outpatient Settings: Synopsis and Strategies. Antibiotics (Basel). 2022; 11(8). PMC: 9405265. DOI: 10.3390/antibiotics11081027. View

13.

Kuo S, Shih S, Lauderdale T, Chang I, Chen Y, Hsiung C . Policy-driven revolution of prescription record in outpatient use of fluoroquinolones. J Microbiol Immunol Infect. 2018; 53(1):133-140. DOI: 10.1016/j.jmii.2018.05.002. View

14.

Diaz-Madriz J, Cordero-Garcia E, Chaverri-Fernandez J, Zavaleta-Monestel E, Murillo-Cubero J, Piedra-Navarro H . Impact of a pharmacist-driven antimicrobial stewardship program in a private hospital in Costa Rica. Rev Panam Salud Publica. 2020; 44:e57. PMC: 7498282. DOI: 10.26633/RPSP.2020.57. View